Moleculin Biotech is trading 17.6% up at $1.20 in pre-market action, rebounding after two sessions of steep losses that drove shares from $2.19 down to $1.02.
- The bounce appears to reflect short-term stabilization and bargain hunting following the sharp decline, as there is currently no fresh company-specific news or filings tied to the move.
- The recovery is occurring against a broadly positive equity backdrop, with major index futures trading modestly higher.